TLDR
- Moderna stock fell 10.7% on July 10, 2026, dropping $8.17 to close at $68.39
- Insiders sold $6.2 million worth of stock in the past three months, with zero buying
- Q1 EPS came in at -$3.40, missing estimates of -$3.02, though revenue of $389M beat forecasts of $236.37M
- Wall Street’s average rating is “Reduce” with a consensus price target of $38.27
- QRG Capital Management opened a new position, buying 13,666 shares worth ~$694,000
Moderna stock took a sharp hit on July 10, 2026, falling 10.7% — a drop of $8.17 — to close at $68.39. The move adds to a broader pattern of pressure on the biotech.
The stock opened that day at $76.56. Moderna’s 52-week range runs from $22.28 to $85.60, so the current price sits in the upper half of that band — but the recent slide suggests the air up there is getting thin.
The most recent earnings report, released May 1, didn’t do the stock any favors. Moderna posted a loss of $3.40 per share, worse than the -$3.02 analysts had expected. That’s a miss, and the market tends to remember those.
Revenue was a different story. The company brought in $389 million for the quarter, blowing past the $236.37 million consensus estimate. That’s a 260.2% jump compared to the same period last year.
Still, a revenue beat can only go so far when profitability remains elusive. Moderna carries a negative net margin of 143.55% and a negative return on equity of 26.64%.
Insider Selling Adds to the Pressure
Insiders have been heading for the exit. Over the past three months, they sold $6.2 million worth of stock — and bought none.
Director Noubar Afeyan sold 9,263 shares on May 21 at an average price of $46.84, cutting his position by 70.24%. President Stephen Hoge sold 53,336 shares on June 15 at $51.37 per share, a transaction totaling roughly $2.74 million.
Those sales were made under pre-arranged 10b5-1 plans, which are scheduled in advance. But the sheer volume of selling tends to catch investor attention.
Insiders collectively own 10.80% of the stock. Institutional investors hold 75.33%.
Wall Street Stays Cautious
Analyst sentiment isn’t exactly a ringing endorsement right now. Of the 18 analysts covering Moderna, two rate it a Buy, eleven say Hold, and five say Sell. The average rating works out to “Reduce.”
The consensus price target sits at $38.27 — well below where the stock is currently trading.
Morgan Stanley recently raised its price target from $33 to $39 with an “equal weight” rating. Goldman Sachs moved its target from $43 to $49 with a “neutral.” Bank of America bumped its target from $34 to $38 but kept an “underperform” rating.
Weiss Ratings maintained a “sell (d-)” on June 12.
On the institutional side, QRG Capital Management opened a new position in Q1, picking up 13,666 shares worth about $694,000. A handful of other smaller funds also added positions, though the amounts were modest.
Moderna’s GF Score stands at 58 out of 100. Financial Strength rates 7/10, Growth 7/10, but Profitability comes in at just 3/10.
The 50-day moving average is $55.75. The 200-day moving average is $49.53. Sell-side analysts as a group expect Moderna to post -$6.51 EPS for the full year.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
